Natural chemical drug production research institute
Production and research company of antioxidant product
(antioxidant dressing, macular degeneration treatment, cardiovascular treatment)
|Product||Pharmaceutical Raw Material for Macular Degeneration Treatment||Atherosclerosis Treatment||First-Aid Antioxidant Dressing & Burn Ointment|
|Characteristic||Zeaxanthin is the material of Highly purified microalgae
The Highest Value among the purified products(Lutein, Meso-Zeaxanthin)
|9-cis β-Carotene is discomposed into two substances, 9-cis Retinoid which break down fat cells in the blood and All-Trans-Retinoid that neutralize blood clotting by acting on the thrombus. Both of them have efficacy in the treatment of atherosclerosis.||These products contain the Beta-carotene, which is extracted by first purification of microalgae, and it is coated with water-soluble Chitosan.
It solve the problems of conventional Liposoluble Vaseline gauze which is caused the skin absorption and secondary inflammation.
|Market Value||The market size of the macular degeneration is about USD 4billion in 2014 and CAGR 7.8%. It is estimated to reach USD 8billion by 2023.||Cardio-cerebrovascular disease is #1 cause of death in the world
The global Atherosclerosis therapeutics market stood at $35 billion in 2012 and will grow at $45 billion by 2022.
|Business Value||The macular degeneration drugs in Korea are all import-dependent and most of the treatments contain about 25% Zeaxanthin.
We are in business agreement with Pharmaceutical Company ‘H’(No.1 Korea company in prescription medicine of Eye Drop domestic technology).
|We are the only company related to Atherosclerosis therapeutics in Korea Bio-Venture and hold the patent about 9-cis β-Carotene purification process.||Complete the certification evaluation by KCL (Korea Conformity Laboratories) Enable to produce from 2019.04
Enter the market to reduce initial marketing budget through military supply